Healthy Participants
Conditions
Brief summary
This Phase 1 study in healthy adults looks at whether sevabertinib changes how the body handles metformin. The study is based on the idea that sevabertinib may block kidney transporters (proteins that move medicines) called MATE1 and MATE2-K, which help remove metformin from the body. Each participant receives a single dose of metformin alone, and later receives sevabertinib for several days and then takes metformin again while still taking sevabertinib. The study aims to learn how metformin, gets into, moves through, and out of the body when it is administered with sevabertinib. This is called "Pharmacokinetics". Furthermore, the study will help us learn about the safety and tolerability of sevabertinib and metformin when given alone or in combination.
Interventions
DRUGMetformin
Immediate-release tablet, 500 mg; administered as a single 500 mg oral dose in Intervention Period 1 (Day 1) and as a single 500 mg oral dose in Intervention Period 2 (Day 1 of the combination phase, after sevabertinib pre-treatment)
DRUGSevabertinib (BAY 2927088)
Film-coated tablet, 10 mg; administered as 20 mg BID (oral) pre-treatment in Intervention Period 2 and continued 20 mg BID during co-administration with metformin
Sponsors
Bayer
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Intervention model description
This is a Phase 1, single-center, open-label, non-randomized, fixed sequence, crossover study in healthy participants using an intra-individual comparison (metformin alone vs. metformin with sevabertinib)
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
Inclusion: * Participant must be 18 to 55 years of age inclusive, at the time of signing the informed consent. * Participants who are overtly healthy as determined by the investigator or medically qualified designee based on medical evaluation including medical history, physical examination, 12-lead ECG, and clinical laboratory tests. * Participant is a non-smoker who has not used tobacco- or nicotine-containing products for at least 6 months before the first study intervention administration. * Body mass index (BMI) within the range 18.5 to 30.0 kg/m² (inclusive) and a body weight of at least 50 kg at screening. * Female, of non-childbearing potential only (see Section 10.4.1). Females must not be pregnant or breastfeeding, and must be documented as of non-childbearing potential (WONCBP). A negative pregnancy test is required Exclusion: * Existing relevant diseases of vital organs (e.g., cardiovascular, liver, gastrointestinal, renal, respiratory, or central nervous system diseases) or other organs (e.g., diabetes mellitus). * Known history of hypersensitivity to sevabertinib, metformin, or any of their excipients. * History of known or suspected malignant tumors. * Regular use of medicines within 4 weeks prior to screening. * Administration of strong or moderate inhibitors or inducers of CYP3A4, P-gp, MATE1/2-K, or OCT2 within 4 weeks or 5 half-lives prior to the first study intervention administration, whichever is longer. * Use of any prescription drug or over-the-counter (OTC) medication within 2 weeks or 5 half-lives of the prescription medication prior to the first study intervention administration (whichever is longer), except for occasional use of acetaminophen (up to 2 g/day) within 7 days prior to the first study intervention administration. * Use of supplements or herbal remedies within 2 weeks prior to the first study intervention administration, except for vitamins. * Excessive intake of methylxanthine-containing drinks or food (e.g., coffee, tea, chocolate) as judged by the investigator. Excessive intake of methylxanthine is defined as the regular consumption of more than 600 mg of caffeine per day (e.g., \>5 cups of coffee) or would likely be unable to refrain from the use of methylxanthine-containing beverages and food during confinement at the clinic. * Clinically relevant findings in the ECG such as a second- or third-degree atrio-ventricular block, prolongation of the average QRS complex over 120 msec or of the QTc (Fridericia correction) interval over 450 msec or any other finding which in the opinion of the investigator will hinder participant's safety at screening or check-in (Day-1). * Positive results for hepatitis B virus surface antigen, hepatitis B virus core antibody, hepatitis C virus antibodies, human immunodeficiency virus antibodies 1 and/or 2 at screening. * Estimated creatinine clearance \<90 mL/min according to Cockcroft-Gault formula (at screening). * Positive urine drug and cotinine screening at screening or check-in (Day-1). * Positive urine alcohol test at screening or check-in (Day-1). * Unable/unwilling to comply with study restrictions.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AUC (Area Under the Curve) of metformin | Relative to metformin administration on Study Day 1 un until Study Day 4 | Assessed for metformin with and without sevabertinib (Metformin alone vs Metformin + sevabertinib). |
| AUC(0-tlast) (Area Under the Curve from time 0 to tlast) of metformin | Relative to metformin administration on Study Day 1 un until Study Day 4 | Assessed for metformin with and without sevabertinib (Metformin alone vs Metformin + sevabertinib). |
| Cmax (Maximum Plasma Concentration) of metformin | Relative to metformin administration on Study Day 1 un until Study Day 4 | Assessed for metformin with and without sevabertinib (Metformin alone vs Metformin + sevabertinib). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with treatment-emergent adverse events (TEAEs) | From the start of study intervention until the last follow-up visit, up to 7 days after the last administration of study intervention. | The number of participants with TEAEs will be summarized by study intervention using Medical Dictionary for Regulatory Activities (MedDRA) terms. |
| Severity of treatment-emergent adverse events (TEAEs) | From the start of study intervention until the last follow-up visit, up to 7 days after the last administration of study intervention. | Intensity of AEs should be documented using the National Cancer Institute’s Common Terminology Criteria for Adverse Events (NCI-CTCAE, v.5.0). |
Countries
United States
Contacts
CONTACTTherapeutic Area Head
Outcome results
None listed